GILEAD SCIENCES, INC. is 150.8x more valuable than Cullinan Therapeutics, Inc. by market capitalization ($150.83 B vs $1.00 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CGEM | GILD |
|---|---|---|
| Market cap | $1.00 B | $150.83 B |
| US-listed rank | #2637 | #99 |
| Revenue (latest FY) | $0.00 | $29.44B |
| Net income (latest FY) | -$219.88M | $8.51B |
| Net margin | - | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 435 | 981 |
GILEAD SCIENCES, INC. is 150.8x more valuable than Cullinan Therapeutics, Inc. by market capitalization ($150.83 B vs $1.00 B).
In their latest fiscal years, Cullinan Therapeutics, Inc. reported $0.00 in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Cullinan Therapeutics, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.